Multiple Myeloma Market Outlook 2026-2034: by Drug Class (Proteasome Inhibitors, Immunomodulators, Anti-CD38 mAbs, Anti-BCMA Therapies, CAR-T & Cell-based Therapies, Others), Route of Administration, Therapy Type, Distribution Channel

The Multiple Myeloma Market is estimated at US$29.3 billion in 2026 and is projected to grow at a CAGR of 7.1% to reach US$50.7 billion by 2034.

Market Overview

The Multiple Myeloma Market covers therapies, diagnostics, and care pathways focused on the treatment and management of multiple myeloma across specialty oncology environments.

Relevant uses and settings include hematology clinics, hospital oncology, maintenance therapy, transplant related care, relapse management, and supportive treatment programs. Commercial considerations include high treatment cost, relapse risk, complex therapy sequencing, reimbursement pressure, and the need to manage side effects over prolonged care journeys.

Market Segmentation

By Drug Class

• Proteasome Inhibitors
• Immunomodulators (IMiDs)
• Anti-CD38 mAbs
• Anti-BCMA Therapies (mAbs, ADCs)
• CAR-T & Cell-based Therapies
• Others (HDACi, Alkylating Agents)

By Route of Administration

• Oral
• Intravenous
• Sub-cutaneous

By Therapy Type

• Monotherapy
• Combination Therapy

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Key Companies Analysed

• Johnson & Johnson
• Bristol Myers Squibb
• Sanofi
• Pfizer
• Takeda
• GSK
• Amgen
• AbbVie
• Regeneron
• Roche
• Merck
• Novartis
• Karyopharm Therapeutics
• Ono Pharmaceutical
• Genmab
• Legend Biotech
• Arcellx
• Cellectar Biosciences
• Ichnos Glenmark Innovation
• Biogen

Geographic Coverage

• North America - Market data and outlook to 2034
  • United States
  • Canada
  • Mexico
  
  
• Europe - Market data and outlook to 2034
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Netherlands
  • Switzerland
  • Poland
  • Sweden
  • Russia
  
  
• Asia-Pacific - Market data and outlook to 2034
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Malaysia
  • Vietnam
  
  
• Middle East and Africa - Market data and outlook to 2034
  • Saudi Arabia
  • South Africa
  • Iran
  • UAE
  • Egypt
  
  
• South and Central America - Market data and outlook to 2034
  • Brazil
  • Argentina
  • Chile
  • Peru
  
  

*We can include data and analysis of additional countries on demand.

Report Delivery and Support

• Updated PDF report and an MS Excel workbook containing market tables and figures.
• 7-day post-sale analyst support for clarifications and in-scope supplementary data.
• Complimentary report update covering the latest available data and relevant market developments.

This product will be delivered within 1-3 business days.